← Back to Home

Costs and enrollment timelines slow progress as Nuvig terminates NVG-2089 trial in neuroimmune disease

A new drug designed to mimic the effects of immunoglobulin is narrowing its development efforts in rare neurological disease. Nuvig says costs and timelines drove the trial termination, while its immune thrombocytopenia trial continues, with efficacy still awaiting data.

By SURL BioNews

Bringing new drugs for rare diseases to patients requires not only demonstrating efficacy but also overcoming enrollment and cost hurdles. Nuvig Therapeutics has halted development of the fusion protein NVG-2089 in chronic inflammatory demyelinating polyneuropathy (CIDP), terminating a Phase 2 trial; a Phase 2 study of the same candidate in immune thrombocytopenia (ITP) continues.

Fierce Biotech reported on October 6 that CEO David Woodhouse said the company made the decision earlier this year because the CIDP study’s anticipated costs and enrollment timelines would limit the pace of the program’s progress. He emphasized that the decision was unrelated to safety. The Catalyst Brief’s report the following day also cited this explanation, but its information likewise came from Fierce Biotech and was not a separate, independent safety assessment.

Trial records show the extent of the pullback. According to registry updates tracked by LARVOL DELTA, the INVGOR trial’s status changed from “active, not recruiting” to “terminated,” with a business decision listed as the reason; enrollment was originally planned at 60 participants, but actual enrollment ultimately totaled 14. The records also show that enrollment had already closed in April 2026. The news therefore discloses an earlier decision and subsequent status updates and should not be interpreted as recruitment suddenly stopping in October.

In CIDP, the immune response damages the myelin sheath surrounding peripheral nerves, causing limb weakness, numbness, and abnormal sensations. Nuvig aims to use a recombinantly produced human IgG1-Fc fusion protein to mimic some of the immunomodulatory functions of intravenous immunoglobulin (IVIg). According to the design previously disclosed by the company, NVG-2089 activates anti-inflammatory regulatory pathways through type II Fc receptors, with the goal of easing the supply and administration burdens associated with plasma-derived IVIg; these potential advantages still require validation in patient trials.

Going forward, NVG-2089’s clinical development will focus more heavily on ITP. This disease involves the immune system attacking platelets, potentially affecting normal blood clotting. Woodhouse said the company expects to share data from both the CIDP and ITP studies in the coming months and announce the next indication it plans to explore, with no layoffs or restructuring currently planned. NVG-2089 remains Nuvig’s only clinical-stage asset.

For this drug, stopping a study in one indication is not enough to resolve questions about its overall therapeutic potential. The report provided no Phase 2 efficacy results or complete adverse event data, and the company’s statement that the decision was “unrelated to safety” cannot substitute for public data. With only 14 participants enrolled in the CIDP study, the scope of conclusions its data can support still depends on the actual study design, follow-up duration, and analysis results; the ongoing ITP trial will provide another opportunity to test this immunomodulatory strategy.

References

  1. Fierce Biotech
  2. LARVOL DELTA
  3. The Catalyst Brief